New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:01 EDTABBVAbbVie presents results from Phase 1 study with ABT-414
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme. Specifically, one patient experienced a complete response (CR) and three patients experienced partial responses as measured with the Revised Assessment in Neuro-Oncology criteria. Later stage clinical trials are being planned to continue to investigate ABT-414 in patients with glioblastoma multiforme.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
June 24, 2015
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use